News & Updates

Among people with nonalcoholic fatty liver disease (NAFLD), those who are lean appear to be at higher risk of death than their overweight and obese counterparts despite having fewer metabolic comorbidities, a study has shown.

Treatment with mesalamine may only have modest efficacy for the global symptoms of irritable bowel syndrome (IBS), specifically IBS that causes increased diarrhoea, according to the results of a meta-analysis. However, the quality of evidence appears to be low.

First-line treatment of advanced renal cell carcinoma (aRCC) with nivolumab plus cabozantinib (N+C) results in sustained survival and response benefits at 3 years minimum follow-up, which is consistent with previous follow-ups, according to a study presented at the 2023 ASCO GU Cancers Symposium.

Success rates of clinical trials in gastric cancer tend to improve with the use of implementing biomarkers, receptor-targeted therapies, and biologics in clinical development, suggests a recent study.